Abeona Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Launch momentum is strong following resolution of manufacturing issues, with four centers active and plans to expand to five to seven this year. Over 50 patients have been identified, high conversion rates are seen, and manufacturing capacity is scaling to meet demand. Profitability is targeted for 2026 with continued process optimization.
Fiscal Year 2025
-
ZEVASKYN's commercial launch is ramping up with strong patient demand, robust payer coverage, and expanding treatment center network. 2025 saw a return to profitability driven by a major voucher sale, and operational execution in 2026 is expected to drive further growth.
-
ZEVASKYN's commercial launch is progressing with strong demand, expanding QTC network, and improved manufacturing processes. Reimbursement is robust with a new J Code and full Medicaid coverage. Pipeline advances include an FDA-endorsed ophthalmology program, with profitability expected in early 2026.
-
Operational progress continued with ZEVASKYN's launch, despite a Q4 2025 shift for first patient treatment due to assay optimization. Patient demand and QTC network doubled, broad payer coverage achieved, and profitability is projected for the first half of 2026.
-
ZevaSkin™ launched as the first gene therapy for RDEB, showing strong demand, positive payer coverage, and multi-year healing benefits. With a $4 billion market opportunity and profitability projected in early 2026, manufacturing and patient access are being rapidly scaled.
-
ZEVASKYN's commercial launch for rDEB is seeing strong early demand, broad payer coverage, and rapid patient uptake, with manufacturing and treatment capacity scaling to meet needs. Repeat treatments are anticipated, and a robust pipeline is in development.
-
FDA approval and early launch of ZEVASKYN for RDEB drove strong patient and payer interest, with first revenues expected in Q3 2025 and profitability projected for early 2026. Financials were boosted by a PRV sale, and manufacturing capacity is set to expand by mid-2026.
-
ZEVASKYN's launch is progressing with strong patient and payer interest, five treatment centers targeted for activation by year-end, and manufacturing capacity scaling to support growth. Financial outlook is positive, with profitability expected in early 2026 and additional upside from partnered programs.
-
FDA approval and commercial launch of ZivaSkin mark a pivotal transition to revenue generation, supported by strong patient and physician demand, robust financials, and outcome-based payer agreements. PRV sale proceeds extend cash runway through projected profitability in early 2026.
-
Pz-cel, a one-time gene therapy for RDEB, is nearing FDA review with strong clinical results and a favorable safety profile. Commercial launch preparations target a $2B+ U.S. market, with initial focus on five centers and plans to scale manufacturing and expand globally.
Fiscal Year 2024
-
PZ-cel is on track for potential FDA approval and Q3 2025 launch, targeting a $2B+ U.S. market for RDEB with initial supply constraints and strong patient, physician, and payer interest. Cash reserves support operations into 2026, with international expansion planned post-approval.
-
The company is advancing pz-cel, a cell therapy for severe RDEB, with strong clinical data and an FDA decision expected by April 29. Manufacturing capacity is set to ramp up through 2025, targeting a core U.S. market of 750 patients, with a projected price above $1.5 million per treatment.
-
FDA accepted the BLA resubmission for pz-cel, setting a PDUFA date for April 2025. Commercial launch preparations and manufacturing expansion are underway, with strong market interest and a cash runway into 2026. Net loss increased due to non-cash warrant remeasurement and higher operating expenses.
-
pz-cel is positioned to address significant unmet needs in RDEB, with strong clinical data, patient advocacy, and payer support. Regulatory resubmission is on track for the second half of the year, and commercial launch preparations are underway, with expansion plans tied to demand and manufacturing capacity.
-
Pz-cel offers durable wound healing and pain reduction for severe recessive dystrophic EB, with strong long-term safety and a single-application approach. Regulatory resubmission is on track, commercial readiness is advancing, and payers show strong support for coverage and reimbursement.
-
Progress continues toward Pz-cel BLA resubmission in H2 2024, with FDA alignment on key CMC items and strong financial resources supporting operations into 2026. Commercial launch preparations advance, and payer feedback is favorable for broad access post-approval.
-
The lead cell therapy program for RDEB shows durable efficacy in the most challenging wounds, with a strong safety profile and no efficacy or safety issues raised by regulators. BLA resubmission is on track for Q3/Q4, and commercial launch preparations are advancing, supported by a solid cash position.
-
The lead program pz-cel demonstrated durable wound closure in RDEB and is progressing toward FDA resubmission in the second half of 2024 after addressing CMC-related CRL items. Commercial launch is planned at select high-volume centers, with strong physician interest and a well-defined patient base.